This is a working overview of mitochondrial biogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-25. Anything still debated is marked as such rather than presented as settled.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
In 2025, Willis underwent keyhole heart surgery after medical investigations revealed that she had a congenital hole in her heart which she had been unaware of for 48 years. The condition was discovered following routine checks and further investigation after an MRI scan identified an enlargement in her heart. Willis underwent the procedure at the Royal Brompton Hospital and later publicly thanked the medical staff who treated her.
== Awards == German Innovation Award. Excellence in Business to Business – Pharmaceuticals, Winner 2019 German Innovation Award, Fortibone January 2020 Nutra Ingredients Awards. Ingredient of the Year: Healthy Ageing – Fortibone, GELITA – 2018, Winner 2018, January 2020 Life PR Award: German Innovation Award in gold for innovative detergent additive Novotec CB800, June 6, 2018 Nutraceuticals World: Top 100 Innovative Companies in Germany, Category "Innovative Processes" Cannes Corporate Media & TV Awards 2016: Four Dolphins for the company Video "You can see". Gold in category corporate videos and silver in the categories marketing films – B2B, information films and visitors films German Brand Award for successful brand management in the category "Industry Excellence in Branding", 2016 "Intermedia-globe Award" in gold, World Media Festival June 22, 2016 Frost & Sullivan Award, "European Health Ingredient of the Year" – 2008 New Hope, "GELITA Wins Frost & Sullivan Award European Health Ingredient of the Year 2008"
Two notable sources of rubidium are the rich deposits of pollucite at Bernic Lake, Manitoba, Canada, and the rubicline ((Rb,K)AlSi3O8 found as impurities in pollucite on the Italian island of Elba, with a rubidium content of 17.5%. Both of those deposits are also sources of caesium.
Additional requirements for rations include having a minimum shelf life of three years, being deliverable by air, being consumable in worldwide environments, and providing a complete nutritional profile. The new T-rations have been improved upon by increasing acceptable items and provide high quality meals while in the field. Freeze-dried coffee was also incorporated by replacing spray-dried coffee in the Meal, Ready-to-Eat category.
According to the Panel of Experts on Yemen established pursuant to Security Council resolution 2140, the Houthis have carried out a wide range of human rights violations, including violations of international humanitarian law and abuse of women and children. Children as young as 13 have been arrested for "indecent acts" for alleged homosexual orientation or "political cases" when their families do not comply with Houthi ideology or regulations. Minors share cells with adult prisoners, and according to unspecified reports that the Panel has deemed "credible", boys held in Al-Shahid Al-Ahmar police station in Sana'a are systematically raped. Aside from the Panel of Experts, London-based Arabic newspaper Asharq Al-Awsat alleges that the Houthis have revived slavery in Yemen.
Sources: en.wikipedia.org
== First generation GcMAF == Gc protein-derived macrophage-activating factor (GcMAF). GcMAF initially conceptualized by Nobuto Yamamoto in 1991, has been researched as a possible cancer treatment. Previous research efforts involved the isolation of Gc protein (1f1f subtype) from human serum through an affinity column modified with 25-hydroxyvitamin D3. GcMAF was enzymatically derived from the isolated Gc protein.
== Side effects == Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear. A new wave of fentanyl analogues and associated deaths began in around 2014 in the US, and have continued to grow in prevalence; especially since 2016 these drugs have been responsible for hundreds of overdose deaths every week.
Vecuronium and pancuronium have an onset of 2 to 5 minutes in adults. The time it takes to recover 25% of neuromuscular control after vecuronium and pancuronium therapy are 25 to 40 minutes and 60 to 80 minutes respectively. Acetylcholinesterase inhibitor
=== Impersonation attempts === Despite a seven-page document written by Twitter's content moderation team, on November 9, Twitter Blue launched with verification exclusively on iOS. Upon introducing paid verification, various individuals in sports Twitter were impersonated, such as sports writer Adam Schefter and basketball player LeBron James, with tweets announcing the supposed ousting of Las Vegas Raiders head coach Josh McDaniels or James' trade from the Los Angeles Lakers, respectively. As impersonation accounts began appearing for Nintendo and Tesla—the latter being owned by Musk—the official label returned. Other individuals and companies impersonated include former president Donald Trump, video game company Valve, and former New York City mayor Rudy Giuliani. One account impersonating the beverage corporation PepsiCo praised the superiority of Coca-Cola. Twitter paused signups for Twitter Blue on November 11; according to a Slack message obtained by Platformer reporter Zoë Schiffer, the company paused subscriptions to deal with impersonation attempts. Musk believed that impersonation would be resolved if Apple handed over the credit card information of Twitter Blue subscribers; then head of trust and safety Yoel Roth explained that Apple would not oblige to such a request. The Washington Post published a report on November 11 detailing how reporter Geoffrey Fowler was, with permission from United States senator Ed Markey, impersonating a U.S.
Periodontal pocket formation Gingival ulceration and suppuration Destruction of the alveolar bone and periodontal ligament Tooth mobility, drifting and eventual loss Because bone loss makes its first appearance in the advanced lesion, it is equated with periodontitis, while the first three lesions are classified as gingivitis in levels of increasing severity. The advanced lesion is no longer localized to the area around the gingival sulcus but spreads apically as well as laterally around a tooth and perhaps even deep into the gum tissue papilla. There is a dense infiltrate of plasma cells, other lymphocytes and macrophages. The clusters of perivascular plasma cells still appears from the established lesion. Bone is resorbed, producing scarring and fibrous change.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.